Increase in plasma levels of clozapine and norclozapine after administration of nefazodone.
Khan
A Y
AY
Preskorn
S H
SH
D000328:Adult; D003024:Clozapine / Q000031:analogs & derivatives / Q000097:blood* / Q000378:metabolism / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D010879:Piperazines; D012563:Schizophrenia, Paranoid / Q000097:blood / Q000188:drug therapy; D014230:Triazoles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
D065607:Cytochrome P-450 Enzyme Inhibitors; D010879:Piperazines; D014230:Triazoles; C058272:norclozapine; C051752:nefazodone; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D003024:Clozapine